patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_753391 | REC_0017701 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 7.3 | 70 | female | 1 | 9 | 5.1 | 2 | pembrolizumab 200 mg q3w | 22 | false | MSS | 2026-03-15T05:36:02.585151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101679 | REC_0017702 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.5 | 58 | male | 1 | 6 | 7 | 6 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:02.585990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566725 | REC_0017703 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 15.8 | 65 | female | 1 | 19 | 7.6 | 1 | alectinib 600 mg BID | 25.8 | false | MSS | 2026-03-15T05:36:02.589527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638257 | REC_0017704 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.9 | 70 | female | 1 | 17 | 4.2 | 8 | sotorasib 960 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:36:02.590352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352661 | REC_0017705 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.1 | 68 | female | 0 | 13 | 5.2 | 3 | sotorasib 960 mg daily | 6 | false | MSS | 2026-03-15T05:36:02.591217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574027 | REC_0017706 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7 | 73 | male | 1 | 36 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.1 | false | MSS | 2026-03-15T05:36:02.591979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418430 | REC_0017707 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.6 | 72 | female | 3 | 21 | 4.7 | 5 | sotorasib 960 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:02.593220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918577 | REC_0017708 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.1 | 82 | female | 1 | 15 | 4.1 | 3 | entrectinib 600 mg daily | 20 | true | MSS | 2026-03-15T05:36:02.594013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807247 | REC_0017709 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.3 | 81 | female | 1 | 67 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:36:02.594818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641985 | REC_0017710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.8 | 76 | female | 2 | 10 | 7.2 | 1 | osimertinib 80 mg daily | 26.6 | true | MSI-H | 2026-03-15T05:36:02.595679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441379 | REC_0017711 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.9 | 57 | male | 1 | 25 | 6.1 | 4 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:36:02.598968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489834 | REC_0017712 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 9.3 | 69 | female | 1 | 10 | 5.5 | 1 | entrectinib 600 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:02.599841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711400 | REC_0017713 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 64 | male | 1 | 38 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 17 | false | MSS | 2026-03-15T05:36:02.601914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813563 | REC_0017714 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 5 | 74 | male | 3 | 13 | 4.8 | 4 | sotorasib 960 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:02.602764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753392 | REC_0017715 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 34 | 7 | 64 | male | 0 | 56 | 5.2 | 6 | pembrolizumab 200 mg q3w | 15.8 | false | MSS | 2026-03-15T05:36:02.603549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310206 | REC_0017716 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 75 | female | 1 | 60 | 7.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:02.604477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955622 | REC_0017717 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.3 | 69 | male | 1 | 18 | 4.4 | 1 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:36:02.605342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316475 | REC_0017718 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 13.8 | 57 | female | 1 | 20 | 5.6 | 2 | sotorasib 960 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:36:02.606195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212553 | REC_0017719 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 19.1 | 66 | female | 1 | 20 | 5.1 | 7 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:36:02.607367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516530 | REC_0017720 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 16.2 | 72 | female | 1 | 3 | 5.5 | 0 | alectinib 600 mg BID | 44.1 | false | MSS | 2026-03-15T05:36:02.612695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977220 | REC_0017721 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 3.7 | 68 | female | 1 | 38 | 7.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 44.3 | false | MSS | 2026-03-15T05:36:02.613567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926460 | REC_0017722 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.3 | 72 | female | 1 | 7 | 6.7 | 1 | alectinib 600 mg BID | 5.5 | false | MSI-H | 2026-03-15T05:36:02.615018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663128 | REC_0017723 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 12.2 | 51 | female | 0 | 16 | 6.1 | 4 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.618703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131848 | REC_0017724 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 18.6 | 71 | female | 1 | 19 | 4.9 | 5 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:36:02.619679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379778 | REC_0017725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11 | 64 | female | 1 | 12 | 4.5 | 3 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:36:02.623425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684806 | REC_0017726 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.5 | 64 | male | 0 | 13 | 6.5 | 7 | entrectinib 600 mg daily | 5.2 | false | MSI-H | 2026-03-15T05:36:02.624514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716257 | REC_0017727 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.4 | 64 | female | 1 | 15 | 6.9 | 2 | pembrolizumab 200 mg q3w | 19 | false | MSS | 2026-03-15T05:36:02.625492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520556 | REC_0017728 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.9 | 69 | female | 0 | 74 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:36:02.626284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242255 | REC_0017729 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 16.1 | 52 | female | 0 | 16 | 4 | 3 | pembrolizumab 200 mg q3w | 15.1 | false | MSI-H | 2026-03-15T05:36:02.627283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723724 | REC_0017730 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 3 | 73 | female | 1 | 20 | 6.2 | 7 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:02.628226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192583 | REC_0017731 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.8 | 65 | female | 0 | 19 | 4.5 | 2 | osimertinib 80 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:36:02.629135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415678 | REC_0017732 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 16.1 | 65 | female | 0 | 4 | 5.7 | 1 | pembrolizumab 200 mg q3w | 23.2 | true | MSI-H | 2026-03-15T05:36:02.629885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184685 | REC_0017733 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.4 | 65 | female | 1 | 55 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:36:02.630960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630843 | REC_0017734 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.8 | 76 | female | 2 | 16 | 4.2 | 7 | osimertinib 80 mg daily | 5.9 | false | MSS | 2026-03-15T05:36:02.631849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295053 | REC_0017735 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7.2 | 72 | male | 1 | 59 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.3 | false | MSS | 2026-03-15T05:36:02.632823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969661 | REC_0017736 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 6.7 | 72 | female | 2 | 10 | 8 | 0 | alectinib 600 mg BID | 15.5 | true | MSS | 2026-03-15T05:36:02.633678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967398 | REC_0017737 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7.7 | 55 | male | 0 | 18 | 7 | 7 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:02.636546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662830 | REC_0017738 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.2 | 60 | female | 1 | 35 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 21.1 | false | MSS | 2026-03-15T05:36:02.637422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796970 | REC_0017739 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 15.4 | 60 | male | 0 | 11 | 6.4 | 6 | sotorasib 960 mg daily | 4.3 | false | MSI-H | 2026-03-15T05:36:02.640162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625624 | REC_0017740 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.2 | 75 | female | 2 | 2 | 5 | 2 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:02.641155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339662 | REC_0017741 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.4 | 65 | female | 1 | 21 | 5.7 | 2 | alectinib 600 mg BID | 19.6 | false | MSS | 2026-03-15T05:36:02.641937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169235 | REC_0017742 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 10.3 | 83 | female | 1 | 4 | 6.4 | 2 | pembrolizumab 200 mg q3w | 27.9 | false | MSI-H | 2026-03-15T05:36:02.642862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677062 | REC_0017743 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 16.4 | 72 | female | 1 | 16 | 3.7 | 1 | osimertinib 80 mg daily | 18.3 | true | MSS | 2026-03-15T05:36:02.647761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393931 | REC_0017744 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.4 | 66 | female | 0 | 12 | 6.5 | 4 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:02.651021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507538 | REC_0017745 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 10.1 | 67 | female | 1 | 13 | 5.5 | 3 | pembrolizumab 200 mg q3w | 8.5 | false | MSS | 2026-03-15T05:36:02.652003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596451 | REC_0017746 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.8 | 68 | female | 0 | 20 | 5.3 | 6 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:36:02.653351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812925 | REC_0017747 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 13 | 12.7 | 76 | female | 1 | 14 | 6 | 8 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:02.654160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182471 | REC_0017748 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15 | 60 | male | 1 | 13 | 4.9 | 5 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:02.654971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527308 | REC_0017749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 9.6 | 57 | female | 1 | 66 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:02.655767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212903 | REC_0017750 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 10.5 | 73 | female | 1 | 14 | 2.7 | 0 | entrectinib 600 mg daily | 56 | false | MSI-H | 2026-03-15T05:36:02.659454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880003 | REC_0017751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 36 | 15 | 65 | male | 0 | 19 | 5.3 | 2 | alectinib 600 mg BID | 24.4 | false | MSI-H | 2026-03-15T05:36:02.660453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262484 | REC_0017752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.3 | 69 | male | 0 | 21 | 5.7 | 7 | alectinib 600 mg BID | 15.1 | true | MSS | 2026-03-15T05:36:02.661373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869671 | REC_0017753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 5.1 | 68 | female | 1 | 14 | 6.9 | 6 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:36:02.662172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109287 | REC_0017754 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 8.5 | 63 | female | 1 | 18 | 4 | 3 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:02.662984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459558 | REC_0017755 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10 | 74 | female | 2 | 19 | 7.1 | 7 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:36:02.663817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305899 | REC_0017756 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12.2 | 66 | female | 0 | 12 | 4.5 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:36:02.664742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132080 | REC_0017757 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7 | 65 | female | 0 | 59 | 7.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:36:02.665606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335280 | REC_0017758 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 13 | 2.9 | 47 | female | 0 | 59 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:36:02.666453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673726 | REC_0017759 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.6 | 52 | female | 0 | 30 | 3.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:36:02.667618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813858 | REC_0017760 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.7 | 65 | female | 0 | 21 | 4 | 6 | alectinib 600 mg BID | 9.1 | true | MSS | 2026-03-15T05:36:02.668707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371463 | REC_0017761 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 12.6 | 85 | female | 2 | 2 | 5.9 | 2 | osimertinib 80 mg daily | 21.8 | true | MSS | 2026-03-15T05:36:02.669578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615115 | REC_0017762 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 8 | 67 | female | 1 | 16 | 4.7 | 4 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:02.670418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872119 | REC_0017763 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 14.5 | 56 | male | 0 | 17 | 5.5 | 7 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:02.671280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499447 | REC_0017764 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 9.1 | 59 | female | 1 | 51 | 7.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.2 | true | MSS | 2026-03-15T05:36:02.672271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884410 | REC_0017765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 7.8 | 60 | female | 1 | 18 | 4.5 | 6 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:36:02.673123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735917 | REC_0017766 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.8 | 84 | female | 2 | 57 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:36:02.673964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361983 | REC_0017767 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.4 | 57 | female | 0 | 21 | 5.1 | 6 | sotorasib 960 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:36:02.674822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941400 | REC_0017768 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 4.8 | 72 | female | 2 | 7 | 5.8 | 3 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:36:02.675631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496049 | REC_0017769 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 8.2 | 69 | female | 1 | 11 | 5.6 | 2 | alectinib 600 mg BID | 25.2 | true | MSS | 2026-03-15T05:36:02.676523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481515 | REC_0017770 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 7 | 66 | female | 0 | 13 | 5.5 | 8 | entrectinib 600 mg daily | 17.2 | true | MSS | 2026-03-15T05:36:02.677380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655101 | REC_0017771 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.1 | 61 | male | 0 | 40 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:36:02.678174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676517 | REC_0017772 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.6 | 70 | female | 1 | 18 | 5.3 | 1 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:02.679312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238478 | REC_0017773 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.3 | 76 | female | 1 | 19 | 5.1 | 5 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:36:02.680273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692818 | REC_0017774 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.5 | 67 | female | 0 | 17 | 4.3 | 5 | osimertinib 80 mg daily | 4.8 | false | MSS | 2026-03-15T05:36:02.681149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944175 | REC_0017775 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.8 | 68 | female | 1 | 16 | 5.8 | 4 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:36:02.682045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166594 | REC_0017776 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 6.3 | 71 | female | 2 | 15 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 31.1 | true | MSS | 2026-03-15T05:36:02.682874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712146 | REC_0017777 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 19.1 | 72 | female | 1 | 12 | 2.9 | 3 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:02.683716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333017 | REC_0017778 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.3 | 61 | male | 0 | 11 | 5.4 | 6 | entrectinib 600 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:02.684677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702646 | REC_0017779 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.3 | 59 | male | 1 | 61 | 5.2 | 8 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:36:02.685526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437396 | REC_0017780 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 12.8 | 64 | male | 0 | 21 | 7.2 | 1 | entrectinib 600 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:36:02.686375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421549 | REC_0017781 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.2 | 68 | female | 0 | 24 | 7.4 | 4 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:36:02.687246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413282 | REC_0017782 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.1 | 71 | female | 2 | 13 | 5.6 | 4 | sotorasib 960 mg daily | 9 | true | MSS | 2026-03-15T05:36:02.688200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961454 | REC_0017783 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 13 | 63 | female | 1 | 18 | 4.7 | 2 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:36:02.689089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909815 | REC_0017784 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 67 | female | 1 | 24 | 5.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:36:02.689981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903268 | REC_0017785 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 6.1 | 73 | female | 1 | 15 | 4.6 | 2 | entrectinib 600 mg daily | 26.8 | false | MSS | 2026-03-15T05:36:02.691099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149047 | REC_0017786 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 17.6 | 68 | female | 0 | 4 | 6.1 | 0 | alectinib 600 mg BID | 55.6 | true | MSI-H | 2026-03-15T05:36:02.691997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201492 | REC_0017787 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 7.3 | 79 | female | 2 | 12 | 6.7 | 1 | sotorasib 960 mg daily | 21.5 | true | MSS | 2026-03-15T05:36:02.692978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897611 | REC_0017788 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.5 | 80 | male | 2 | 11 | 5.3 | 3 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:36:02.693875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819360 | REC_0017789 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.6 | 65 | female | 0 | 20 | 3.9 | 5 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:02.694720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970898 | REC_0017790 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.2 | 67 | male | 0 | 64 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:36:02.695544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294202 | REC_0017791 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.6 | 77 | female | 1 | 4 | 6.3 | 2 | osimertinib 80 mg daily | 25.9 | false | MSI-H | 2026-03-15T05:36:02.696482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889025 | REC_0017792 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.3 | 73 | female | 1 | 3 | 5.4 | 6 | sotorasib 960 mg daily | 6.7 | true | MSS | 2026-03-15T05:36:02.697302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639504 | REC_0017793 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 3 | 65 | female | 0 | 21 | 4.3 | 1 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:36:02.698144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346943 | REC_0017794 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.9 | 66 | female | 0 | 73 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.2 | false | MSS | 2026-03-15T05:36:02.699004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886035 | REC_0017795 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 54 | male | 0 | 40 | 4.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:36:02.699848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293318 | REC_0017796 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.9 | 66 | female | 1 | 14 | 5.2 | 6 | sotorasib 960 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:36:02.700782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756698 | REC_0017797 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.3 | 62 | female | 0 | 4 | 4.4 | 3 | alectinib 600 mg BID | 15.7 | false | MSS | 2026-03-15T05:36:02.701559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184611 | REC_0017798 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 2.2 | 69 | male | 0 | 10 | 6.5 | 5 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:02.702712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858492 | REC_0017799 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11 | 64 | male | 1 | 21 | 5.6 | 6 | osimertinib 80 mg daily | 5.3 | true | MSI-H | 2026-03-15T05:36:02.703561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780683 | REC_0017800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 10 | 11.9 | 68 | male | 0 | 4 | 4.7 | 5 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:36:02.704465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.